Cargando…

Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report

Advanced intrahepatic cholangiocarcinoma (iCCA) is not suitable for surgical treatment. Guided by the concept of precision medicine, preoperative systematic treatment may reshape the clinical outcomes of advanced intrahepatic cholangiocarcinoma patients. We describe the case of a 38-year-old female...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ze, Zhang, Wenwen, Wang, Hongguang, Hu, Bingyang, Wang, Zhanbo, Lu, Shichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484748/
https://www.ncbi.nlm.nih.gov/pubmed/34603331
http://dx.doi.org/10.3389/fimmu.2021.744571
_version_ 1784577387550212096
author Zhang, Ze
Zhang, Wenwen
Wang, Hongguang
Hu, Bingyang
Wang, Zhanbo
Lu, Shichun
author_facet Zhang, Ze
Zhang, Wenwen
Wang, Hongguang
Hu, Bingyang
Wang, Zhanbo
Lu, Shichun
author_sort Zhang, Ze
collection PubMed
description Advanced intrahepatic cholangiocarcinoma (iCCA) is not suitable for surgical treatment. Guided by the concept of precision medicine, preoperative systematic treatment may reshape the clinical outcomes of advanced intrahepatic cholangiocarcinoma patients. We describe the case of a 38-year-old female who has been diagnosed with stage IV intrahepatic cholangiocarcinoma with a high tumor mutational burden and positively programmed death-ligand 1 (PD-L1) expression. The patient was treated with programmed cell death 1 (PD-1) inhibitors combined with tyrosine kinase inhibitors (TKIs). After 7 cycles of combination therapy, she underwent radical resection and no tumor cells were found in the postoperative histopathological examination. In addition, the patient’s survival time had reached 25 months, as of August 2021. To date, this is the first case of successful radical resection after combined immunotherapy with TKIs for advanced PD-L1-positive intrahepatic cholangiocarcinoma with a high tumor mutational burden (TMB). The case provides a new approach to the treatment of advanced intrahepatic cholangiocarcinoma.
format Online
Article
Text
id pubmed-8484748
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84847482021-10-02 Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report Zhang, Ze Zhang, Wenwen Wang, Hongguang Hu, Bingyang Wang, Zhanbo Lu, Shichun Front Immunol Immunology Advanced intrahepatic cholangiocarcinoma (iCCA) is not suitable for surgical treatment. Guided by the concept of precision medicine, preoperative systematic treatment may reshape the clinical outcomes of advanced intrahepatic cholangiocarcinoma patients. We describe the case of a 38-year-old female who has been diagnosed with stage IV intrahepatic cholangiocarcinoma with a high tumor mutational burden and positively programmed death-ligand 1 (PD-L1) expression. The patient was treated with programmed cell death 1 (PD-1) inhibitors combined with tyrosine kinase inhibitors (TKIs). After 7 cycles of combination therapy, she underwent radical resection and no tumor cells were found in the postoperative histopathological examination. In addition, the patient’s survival time had reached 25 months, as of August 2021. To date, this is the first case of successful radical resection after combined immunotherapy with TKIs for advanced PD-L1-positive intrahepatic cholangiocarcinoma with a high tumor mutational burden (TMB). The case provides a new approach to the treatment of advanced intrahepatic cholangiocarcinoma. Frontiers Media S.A. 2021-09-17 /pmc/articles/PMC8484748/ /pubmed/34603331 http://dx.doi.org/10.3389/fimmu.2021.744571 Text en Copyright © 2021 Zhang, Zhang, Wang, Hu, Wang and Lu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhang, Ze
Zhang, Wenwen
Wang, Hongguang
Hu, Bingyang
Wang, Zhanbo
Lu, Shichun
Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report
title Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report
title_full Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report
title_fullStr Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report
title_full_unstemmed Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report
title_short Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report
title_sort successful treatment of advanced intrahepatic cholangiocarcinoma with a high tumor mutational burden and pd-l1 expression by pd-1 blockade combined with tyrosine kinase inhibitors: a case report
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484748/
https://www.ncbi.nlm.nih.gov/pubmed/34603331
http://dx.doi.org/10.3389/fimmu.2021.744571
work_keys_str_mv AT zhangze successfultreatmentofadvancedintrahepaticcholangiocarcinomawithahightumormutationalburdenandpdl1expressionbypd1blockadecombinedwithtyrosinekinaseinhibitorsacasereport
AT zhangwenwen successfultreatmentofadvancedintrahepaticcholangiocarcinomawithahightumormutationalburdenandpdl1expressionbypd1blockadecombinedwithtyrosinekinaseinhibitorsacasereport
AT wanghongguang successfultreatmentofadvancedintrahepaticcholangiocarcinomawithahightumormutationalburdenandpdl1expressionbypd1blockadecombinedwithtyrosinekinaseinhibitorsacasereport
AT hubingyang successfultreatmentofadvancedintrahepaticcholangiocarcinomawithahightumormutationalburdenandpdl1expressionbypd1blockadecombinedwithtyrosinekinaseinhibitorsacasereport
AT wangzhanbo successfultreatmentofadvancedintrahepaticcholangiocarcinomawithahightumormutationalburdenandpdl1expressionbypd1blockadecombinedwithtyrosinekinaseinhibitorsacasereport
AT lushichun successfultreatmentofadvancedintrahepaticcholangiocarcinomawithahightumormutationalburdenandpdl1expressionbypd1blockadecombinedwithtyrosinekinaseinhibitorsacasereport